<DOC>
	<DOC>NCT00754871</DOC>
	<brief_summary>This study will be investigated what mechanism of action Dienogest has. The growth of the follicles, the endometrium, the hormones in the blood and the mucus that is produced by the cervix that will be looked upon. Four different dosages of Dienogest (0.5 mg, 1 mg, 2 mg and 3 mg) will be investigated in healthy young women over two cycles, or up to a maximum of 72 days.</brief_summary>
	<brief_title>Pharmacodynamic Characterization of Dienogest</brief_title>
	<detailed_description />
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<criteria>Signed informed consent BodyMassIndex (BMI): 18 30 kg/mÂ² Healthy female volunteers Age 1835 years (smoker not older than 30 years, inclusive) At least 3 months since delivery, abortion or lactation Willingness to use nonhormonal methods of contraception during entire study Contraindications for use of progesteroneonly pills or combined oral contraceptives (e.g. history of venous/arterial thromboembolic disease) Use of systemic or topical medications or substances which oppose the study objectives or which might influence them within 4 weeks prior to start of the pretreatment cycle Clinically relevant findings (blood pressure, physical and gynecological examination, laboratory examination)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>